The Role of EECP in the Management of Chronic Heart Failure Patients 體外反搏治療改善心臟衰竭患者的 機制 和結果

Source From 資料來源 :

The Role of EECP in the Management of Chronic Heart Failure Patients

Balloon counterpulsation has gained widespread acceptance as a therapy for cardiogenic shock. However, over the past four decades a parallel method of noninvasive counterpulsation, enhanced external counterpulsation (EECP), has been defined and developed. Mechanisms of benefit for this technology continue to emerge and include enhanced coronary and other key target organ perfusion beds. Other mechanisms include angiogenesis and enhanced cellular metabolism. Beyond putative mechanisms there is ample evidence for improved and sustained outcomes in patients with and without left ventricular dysfunction. This evidence comes from long-term registry reports and randomized clinical trials. With respect to heart failure (HF), there is registry, pilot trial, and randomized clinical trial evidence of safety and efficacy. This paper summarizes some of the mechanisms and outcomes of EECP in HF patients and helps to elucidate the role of EECP in the management of patients with chronic HF.

「慢性心力衰竭的強化體外反搏: 我們的現狀如何?」

球囊反搏作為一種治療心源性休克的方法已被廣泛接受。然而,在過去四十年中,非侵入性反搏方法:體外反搏治療(EECP)得到了發展。研究發現了它的 機制 :包括增強冠狀動脈和其他主要目標器官的灌注。其他 機制 包括血管生成和細胞代謝增強。除了推測的 機制 外,還有大量證據表明,有左心室功能障礙或無左心室功能障礙的患者都得到了改善和維持。這些證據來自長期登記報告和隨機臨床試驗。關於心臟衰竭(HF),有登記報告、試點試驗和隨機臨床試驗的安全性和有效性證據。本文總結了 EECP 在心臟衰竭患者中的一些 機制 和結果,並幫助闡明 EECP 在心臟衰竭患者中的作用。